2024
Association of cardiovascular diseases with cognitive performance in older adults
Park D, Jamil Y, Babapour G, Kim J, Campbell G, Akman Z, Kochar A, Sen S, Samsky M, Sikand N, Frampton J, Damluji A, Nanna M. Association of cardiovascular diseases with cognitive performance in older adults. American Heart Journal 2024, 273: 10-20. PMID: 38575050, PMCID: PMC11162917, DOI: 10.1016/j.ahj.2024.03.016.Peer-Reviewed Original ResearchAnimal Fluency TestOlder adultsCERAD-DRDSST scoresCardiovascular diseaseNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyCongestive heart failureFree of cardiovascular diseaseFluency testCardiovascular disease subtypesNutrition Examination SurveyAssociation of cardiovascular diseaseAnimal Fluency test scoreCognitive performanceLower cognitive performanceCoronary heart diseaseHeart failureCVD subtypesExamination SurveyAssess cognitive performanceAdultsCognitive functionHeart diseaseScores
2023
Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial
Jamil Y, Park D, Verde L, Sherwood M, Tehrani B, Batchelor W, Frampton J, Damluji A, Nanna M. Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial. The American Journal Of Cardiology 2023, 214: 66-76. PMID: 38160927, PMCID: PMC10923116, DOI: 10.1016/j.amjcard.2023.12.045.Peer-Reviewed Original ResearchStable ischemic heart diseaseAnti-anginal agentIntensive medical therapyIschemic heart diseaseMedical therapyQOL metricsHeart diseaseFindings merit further researchMajor adverse cardiovascular eventsAnti-anginal treatmentBARI 2D trialGreater QoL improvementAdverse cardiovascular eventsMyocardial jeopardy indexCardiovascular eventsCause mortalityCardiovascular endpointsClinical confoundersPatient characteristicsDiabetes mellitusHeart failureTherapy intensityClinical outcomesQOL improvementMyocardial infarctionCarcinoid Heart Disease-Induced Right-Sided Heart Failure as a Culprit for Significant Ascites
Huang Y, Park D, Almoghrabi A, Nanna M. Carcinoid Heart Disease-Induced Right-Sided Heart Failure as a Culprit for Significant Ascites. Case Reports In Gastroenterology 2023, 17: 179-184. PMID: 36974060, PMCID: PMC10039415, DOI: 10.1159/000529633.Peer-Reviewed Original ResearchCarcinoid heart diseaseDiagnosis of carcinoid heart diseaseManagement of carcinoid heart diseaseSerum-ascites albumin gradientHeart diseaseAlcohol use disorderSignificant ascitesNeuroendocrine neoplasmsPortal hypertensionCase reportAlbumin gradientHeart failurePhysical examinationEarly diagnosisUse disorderAscitesFluid analysisPatient outcomesPeritoneal fluid analysisDiagnosisMultidisciplinary approachPatientsEarly interventionDiseaseRelevant specialists
2022
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trialsNational trend of heart failure and other cardiovascular diseases in people living with human immunodeficiency virus
Park D, An S, Romero M, Murthi M, Atluri R. National trend of heart failure and other cardiovascular diseases in people living with human immunodeficiency virus. World Journal Of Cardiology 2022, 14: 427-437. PMID: 36161061, PMCID: PMC9350607, DOI: 10.4330/wjc.v14.i7.427.Peer-Reviewed Original ResearchBurden of cardiovascular diseaseHuman immunodeficiency virusIschemic heart diseaseHeart failureIn-hospital mortalityLength of stayCardiovascular diseaseTotal hospital chargesIncreasing burden of cardiovascular diseaseImmunodeficiency virusInternational Classification of DiseasesCochran-Armitage trend testCardiovascular health risksHospital chargesClassification of DiseasesEffective antiretroviral therapyNational Inpatient SampleClinical ModificationInternational ClassificationLonger life expectancyIncreasing burdenVulnerable populationsPLWHInpatient SampleAntiretroviral therapy